anti-MUC1* monoclonal antibody

Anti-MUC1* monoclonal antibody is a preclinical-stage therapeutic developed by Minerva Biotechnologies for the treatment of various solid tumors. The antibody specifically targets MUC1*, which is the activated, cleaved form of the MUC1 transmembrane protein. While full-length MUC1 is often associated with healthy tissues and provides a protective barrier, MUC1* is the predominant form found on cancer cells where it functions as a potent growth factor receptor, driving tumor proliferation, survival, and metastasis. By binding to the extracellular domain of MUC1*, this monoclonal antibody is designed to block oncogenic signaling and potentially induce antibody-dependent cellular cytotoxicity (ADCC) against tumor cells expressing this specific epitope.

Other names

Anti-MUC1* Monoclonal AntibodyMUC1* monoclonal antibody